Therapy resistance on the RADar in ovarian cancer
Open Access
- 29 March 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 13 (5), e14010
- https://doi.org/10.15252/emmm.202114010
Abstract
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.This publication has 11 references indexed in Scilit:
- Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancerEMBO Molecular Medicine, 2021
- Immunotherapy in Ovarian Cancer: Are We There Yet?Journal of Clinical Oncology, 2019
- Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum MonotherapyMolecular Cancer Research, 2018
- Biomarkers for Homologous Recombination Deficiency in CancerJNCI Journal of the National Cancer Institute, 2018
- PARP inhibitors: Synthetic lethality in the clinicScience, 2017
- Cancer statistics, 2017CA: A Cancer Journal for Clinicians, 2017
- Ovarian cancerNature Reviews Disease Primers, 2016
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Role of the human RAD51 protein in homologous recombination and double-stranded-break repairTrends in Biochemical Sciences, 1998